These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 28637250)
1. Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen. Yumura K; Akiba H; Nagatoishi S; Kusano-Arai O; Iwanari H; Hamakubo T; Tsumoto K J Biochem; 2017 Sep; 162(3):203-210. PubMed ID: 28637250 [TBL] [Abstract][Full Text] [Related]
2. Generation of biparatopic antibody through two-step targeting of fragment antibodies on antigen using SpyTag and SpyCatcher. Akiba H; Takayanagi K; Kusano-Arai O; Iwanari H; Hamakubo T; Tsumoto K Biotechnol Rep (Amst); 2020 Mar; 25():e00418. PubMed ID: 31993343 [TBL] [Abstract][Full Text] [Related]
3. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway. Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794 [TBL] [Abstract][Full Text] [Related]
4. [Bispecific antibodies: what future?]. Pèlegrin A; Robert B Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697 [TBL] [Abstract][Full Text] [Related]
5. Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging. Alam MK; El-Sayed A; Barreto K; Bernhard W; Fonge H; Geyer CR Mol Imaging Biol; 2019 Feb; 21(1):54-66. PubMed ID: 29948640 [TBL] [Abstract][Full Text] [Related]
6. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499 [TBL] [Abstract][Full Text] [Related]
7. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth. Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620 [TBL] [Abstract][Full Text] [Related]
8. Rapid Production of Bispecific Antibodies from Off-the-Shelf IgGs with High Yield and Purity. Mei L; Zappala F; Tsourkas A Bioconjug Chem; 2022 Jan; 33(1):134-141. PubMed ID: 34894663 [TBL] [Abstract][Full Text] [Related]
9. A single homogeneous assay for simultaneous measurement of bispecific antibody target binding. Christian EA; Hussmann GP; Babu M; Prophet M; Mazor Y; Chen W; Grigoriadou C; Lin S J Immunol Methods; 2021 Sep; 496():113099. PubMed ID: 34224737 [TBL] [Abstract][Full Text] [Related]
10. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331 [TBL] [Abstract][Full Text] [Related]
11. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. Biburger M; Weth R; Wels WS J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482 [TBL] [Abstract][Full Text] [Related]
12. A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system. Alam MK; Brabant M; Viswas RS; Barreto K; Fonge H; Ronald Geyer C BMC Biotechnol; 2018 Sep; 18(1):55. PubMed ID: 30200951 [TBL] [Abstract][Full Text] [Related]
13. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714 [TBL] [Abstract][Full Text] [Related]
14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
15. [Construction and characterization of bispecific single-chain antibody fragments SZ-2/SZ-21 against platelet glycoprotein Ib alpha and beta3]. Dai K; An G; Ruan C Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1493-7. PubMed ID: 12509914 [TBL] [Abstract][Full Text] [Related]
16. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Nettelbeck DM; Miller DW; Jérôme V; Zuzarte M; Watkins SJ; Hawkins RE; Müller R; Kontermann RE Mol Ther; 2001 Jun; 3(6):882-91. PubMed ID: 11407902 [TBL] [Abstract][Full Text] [Related]
17. An efficient route to the production of an IgG-like bispecific antibody. Zuo Z; Jimenez X; Witte L; Zhu Z Protein Eng; 2000 May; 13(5):361-7. PubMed ID: 10835110 [TBL] [Abstract][Full Text] [Related]
18. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Jung G; Grosse-Hovest L; Krammer PH; Rammensee HG Cancer Res; 2001 Mar; 61(5):1846-8. PubMed ID: 11280736 [TBL] [Abstract][Full Text] [Related]